• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Alder BioPharmaceuticals - Articles and news items

Clazakizumab, an anti-IL-6 monoclonal antibody for the treatment of rheumatoid arthritis, meets primary endpoint in follow-on Phase 2b clinical trial

Industry news / 5 May 2015 / Victoria White

Clazakizumab has met its primary endpoint in a follow-on Phase 2b clinical trial in adults with moderate to severe rheumatoid arthritis…


Webinar: SIFT-MS: A New Tool for Impurity Profiling in Pharmaceutical ProductsLEARN MORE
+ +